ECC: Diabetes Increased Risk for Developing, Dying from Breast or Colon Cancer

Article

A new meta-analysis indicated that people with diabetes are not only at an increased risk of developing breast and colon cancer, but are also at an increased risk of dying from the diseases.

A new meta-analysis indicated that people with diabetes are not only at an increased risk of developing breast and colon cancer, but are also at an increased risk of dying from the diseases.

The results of the meta-analysis were presented by Kirstin De Bruijn, a PhD student at Erasmus University Medical Center, Rotterdam, the Netherlands, at the 2013 European Cancer Congress.

“Our meta-analysis is the first to combine incidence and death from breast and colon cancer, while excluding all other causes of death,” De Bruijn said in a press release. “We have investigated the link between diabetes and the risk of developing as well as the risk of dying from these cancers.”

De Bruijn and colleagues looked at the results from 20 studies published after 2007 that included data to allow researchers to extract or calculate hazard ratios (HRs) for the relationship between diabetes and breast and colorectal cancer incidence and cancer-specific mortality. The 20 studies included information on more than 1.9 million patients with cancer and with or without diabetes.

Data indicated that patients with diabetes had a 23% increased risk for developing breast cancer (HR = 1.23; 95% CI, 1.12–1.34) and a 26% increased risk for developing colorectal cancer (HR = 1.26; 95% CI, 1.14–1.40) compared with patients without diabetes.

Excluding all other causes of death, patients with diabetes also had a 38% increased risk of dying from breast cancer (HR = 1.38; 95% CI, 1.20–1.58) and a 30% increased risk of dying from colorectal cancer (HR = 1.30; 95% CI, 1.15–1.47) compared with patients without diabetes.

“Cancer patients who are obese and diabetic are an already more vulnerable group of individuals when it comes to surgery, as they have an increased risk of developing complications both during and after surgery,” De Bruijn said in a press release. “If more obese and diabetic patients have to have an operation because of cancer, healthcare costs will increase.”

De Bruijn and colleagues recommended increased efforts to raise awareness of these risks and prevention campaigns designed to highlight the link between obesity, diabetes, and cancer risk.

“For further research, it would be important to study how other, competing risk factors might affect survival, as elderly cancer patients with diabetes are usually diagnosed with other conditions as well,” commented ECCO President Cornelis van de Velde. “Additionally, the potential role of metformin in relation to improved survival and cancer recurrence needs to be studied.”

Recent Videos
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Related Content